vTv Therapeutics Inc. - (VTVT) Social Stream



vTv Therapeutics Inc. - (VTVT): $1.96

-0.06 (-2.97%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About VTVT

$VTVT VOLUME ALERT STRONG BUY REVERSAL is in
BIG NEWS any day from now:
2 important results should come out this quarter
any day from now :
1* " Mechanistic Study of Ketoacidosis with TTP399. The Company began dosing patients in a mechanistic study of TTP399 in people with type 1 diabetes to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal. vTv expects to report topline results from the mechanistic study in the third quarter of 2021
2* "Psoriasis
Multiple Ascending Dose Study with HPP737. The Company began dosing healthy subjects in a phase 1 multiple ascending dose study to assess the safety, tolerability, and pharmacokinetic profile of HPP737, an oral PDE4 inhibitor. This phase 1 study is expected to report topline results in the third quarter and will inform dose selection for a planned phase 2 study in psoriasis."
Market Cap only 170m It's ridiculous !!
insider own 75% of the shares
LONG and STRONG
watch
$CEMI $NURO $PRFX $mrin
GDS_investing, published July 21, 2021

What Else are VTVT Traders Talking About?


Other tickers frequently mentioned alongside VTVT are NURO and PRFX.

Other Notable StockTweets About VTVT


$VTVT STRONG BUY SUPPORT AREA
2 important results should come out this quarter
any day from now :
1* " Mechanistic Study of Ketoacidosis with TTP399. The Company began dosing patients in a mechanistic study of TTP399 in people with type 1 diabetes to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal. vTv expects to report topline results from the mechanistic study in the third quarter of 2021."
2* "Psoriasis
Multiple Ascending Dose Study with HPP737. The Company began dosing healthy subjects in a phase 1 multiple ascending dose study to assess the safety, tolerability, and pharmacokinetic profile of HPP737, an oral PDE4 inhibitor. This phase 1 study is expected to report topline results in the third quarter and will inform dose selection for a planned phase 2 study in psoriasis."

n my opinion at this price it's money on the floor
Market Cap only 160m It's ridiculous !!
LONG and STRONG

GDS_investing, published July 15, 2021

$VTVT Again the emphasis on a European Partnership is solidified in many respects including in their SEC Filings:

10K
Risks Relating to Our Dependence on Third Parties

"We intend to seek collaborative relationships for the development and/or commercialization of our drug candidates, including TTP399. Failure to obtain a collaborative relationship for these candidates, particularly in the European Union"

Article on August 4th 2020
Suggestion a Partner AntiDiabetic BP Company
https://www.healthline.com/diabetesmine/ttp399-future-type1-diabetes-pill

A Partnership prior to Phase 3 Clinical Trial (Common within the Biotech Realm) in 4th Qtr
*An educational guess regarding the window-of-opportunity for a Partnership could be from September 27th when Mechanistic Data for TTP399 will be presented at the EASD Virtual Conference held on September 27th to October 1st, til the 1st week of November when 3rd Qtr report is due.

Chief Scientific Officer Carmen Valcarce confirmed the Vtv will be participating at the EASD Conference 2021.

DamYankee, published July 12, 2021

$VTVT don't want to jinx myself but we are coming close to my 2.11 or better purchase price... Far cry from 2.70
The question is will cantor dilute into the current price or will they play the LPC game and spin it up by inter company trading letting people hold the bag.
50m

eddioo, published July 2, 2021

$VTVT be ready 3
"The vTv team continued to build on the clinical success of our type 1 diabetes program during the quarter by obtaining Breakthrough Therapy designation from the FDA for TTP399 and by initiating a phase 1 study to understand TTP399’s impact on ketoacidosis. The FDA’s grant of Breakthrough is an acknowledgment of the significant unmet need for patients with type 1 diabetes, and the encouraging clinical results we have generated to date,” said Steve Holcombe, president and CEO, vTv Therapeutics. “We look forward to working closely with the FDA to optimize the development pathway for TTP399 to bring this potential treatment to patients with type 1 diabetes as quickly as possible.”"

GDS_investing, published June 29, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5512 seconds.